Skip to Content
Merck

Skip To

P0018

Pomalidomide

≥98% (HPLC), powder, HbF inducer

Synonym(s):

1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide, 4-Amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, Actimid, CC-4047, IMiD 3

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C13H11N3O4
CAS Number:
Molecular Weight:
273.24
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Pomalidomide, ≥98% (HPLC)

ligand

pomalidomide

Quality Level

assay

≥98% (HPLC)

form

powder

reaction suitability

reagent type: ligand

color

yellow

solubility

DMSO: ≥14 mg/mL

storage temp.

2-8°C

SMILES string

Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12

InChI

1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

InChI key

UVSMNLNDYGZFPF-UHFFFAOYSA-N

Gene Information

Application

Pomalidomide has been used:
  • to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptides[1]
  • for apoptosis studies and intracellular calcium analysis[2]
  • as a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells[3]

Biochem/physiol Actions

Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog.
Pomalidomide is an effective fetal hemoglobin (HbF) inducer that downregulates the key &#947-globin repressors, SRY-box transcription factor 6 (SOX6), and BAF chromatin remodeling complex subunit (BCL11A).[3]

Features and Benefits

This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
930563SML2283930571
form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥95%

assay

≥98% (HPLC)

assay

≥95%

Quality Level

100

Quality Level

100

Quality Level

-

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: ≥14 mg/mL

solubility

-

solubility

DMSO: 2 mg/mL, clear

solubility

-

color

yellow

color

-

color

white to beige

color

-


pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Emma C Fink et al.
Blood, 132(14), 1535-1544 (2018-08-02)
Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with del(5q). These molecules lack activity in murine models, limiting investigation of their therapeutic activity or toxicity in vivo. Here, we report the
Yan-Rou Tsai et al.
International journal of molecular sciences, 19(10) (2018-10-24)
Due to its high oxygen demand and abundance of peroxidation-susceptible lipid cells, the brain is particularly vulnerable to oxidative stress. Induced by a redox state imbalance involving either excessive generation of reactive oxygen species (ROS) or dysfunction of the antioxidant
Manh-Cuong Vo et al.
Frontiers in immunology, 9, 1798-1798 (2018-08-21)
We have previously shown that immunization with tumor antigen-loaded dendritic cells (DCs) and the immunomodulating drug, lenalidomide, synergistically potentiates the enhancing antitumor immunity in a myeloma mouse model. In this study, we investigated the immunogenicity of DCs combined with pomalidomide



Global Trade Item Number

SKUGTIN
P0018-25MG04061833213193
P0018-5MG04061834261841

Questions

Reviews

No rating value

Active Filters